Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CelLBxHealthANPCF 3-1 Month Momentum % is 93.20% as of Jul. 31, 2026. The stock has 5 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, CelLBxHealth ranks better than 95.31% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-31), CelLBxHealth's 3-1 Month Momentum % is 93.20%.
The industry rank for CelLBxHealth's 3-1 Month Momentum % or its related term are showing as below:
ANPCF's 3-1 Month Momentum % is ranked better than 95.31% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -4.42
vs ANPCF: 93.20
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
CelLBxHealth 3-1 Month Momentum % Related Terms
ANPCF vs TMO, DHR, IDXX: 3-1 Month Momentum % Comparison
For the Diagnostics & Research subindustry, CelLBxHealth's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CelLBxHealth 3-1 Month Momentum % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, CelLBxHealth's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where CelLBxHealth's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CelLBxHealth (ANPCF) has a 3-1 Month Momentum % of 93.20% as of Jul. 31, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on CelLBxHealth and its competitors. According to the industry distribution chart, CelLBxHealth ranks #10 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 4.7%.
Is CelLBxHealth's 3-1 Month Momentum % too high?
CelLBxHealth's current 3-1 Month Momentum % is 93.20%. Based on the distribution chart, CelLBxHealth ranks #10 out of 213 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does CelLBxHealth's 3-1 Month Momentum % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, CelLBxHealth ranks #10 out of 213 companies for 3-1 Month Momentum %. This places CelLBxHealth in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Diagnostics & Research company?
A good 3-1 Month Momentum % depends on the Medical Diagnostics & Research industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on CelLBxHealth and its competitors. CelLBxHealth's current 3-1 Month Momentum % is 93.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CelLBxHealth stock overvalued right now?
CelLBxHealth (ANPCF) has a current 3-1 Month Momentum % of 93.20%. The current 3-1 Month Momentum % is 93.20%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For CelLBxHealth (ANPCF), the current 3-1 Month Momentum % is 93.20% as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CelLBxHealth PLC is active in the healthcare sector in the United Kingdom. The Company's principal trading activity is undertaken in relation to the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy that is non-invasive cancer diagnostics. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which the majority of its revenue is generated from Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANPCF has been successfully added to your 
